Switch theme
Sign up to access all valuation multiples
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
1997
116
LTM Revenue $16.3M
LTM EBITDA $2.0M
$19.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biomaxima has a last 12-month revenue (LTM) of $16.3M and a last 12-month EBITDA of $2.0M.
In the most recent fiscal year, Biomaxima achieved revenue of $12.4M and an EBITDA of $0.9M.
Biomaxima expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biomaxima valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $16.3M | XXX | $12.4M | XXX | XXX | XXX |
| Gross Profit | $16.3M | XXX | $5.3M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $2.0M | XXX | $0.9M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $1.0M | XXX | -$0.1M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | -1% | XXX | XXX | XXX |
| Net Profit | $0.7M | XXX | $0.2M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biomaxima's stock price is PLN 14 (or $4).
Biomaxima has current market cap of PLN 60.6M (or $16.1M), and EV of PLN 74.8M (or $19.8M).
See Biomaxima trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.8M | $16.1M | XXX | XXX | XXX | XXX | $0.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biomaxima has market cap of $16.1M and EV of $19.8M.
Biomaxima's trades at 1.6x EV/Revenue multiple, and 22.8x EV/EBITDA.
Equity research analysts estimate Biomaxima's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biomaxima has a P/E ratio of 23.6x.
See valuation multiples for Biomaxima and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.1M | XXX | $16.1M | XXX | XXX | XXX |
| EV (current) | $19.8M | XXX | $19.8M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 10.1x | XXX | 22.8x | XXX | XXX | XXX |
| EV/EBIT | 19.1x | XXX | -312.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.6x | XXX | 103.4x | XXX | XXX | XXX |
| EV/FCF | -96.4x | XXX | -4.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiomaxima's last 12 month revenue growth is 28%
Biomaxima's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $46K for the same period.
Biomaxima's rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biomaxima's rule of X is 81% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biomaxima and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 70% | XXX | -46% | XXX | XXX | XXX |
| Rule of 40 | 54% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 81% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $46K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomaxima acquired XXX companies to date.
Last acquisition by Biomaxima was XXXXXXXX, XXXXX XXXXX XXXXXX . Biomaxima acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biomaxima founded? | Biomaxima was founded in 1997. |
| Where is Biomaxima headquartered? | Biomaxima is headquartered in Poland. |
| How many employees does Biomaxima have? | As of today, Biomaxima has 116 employees. |
| Is Biomaxima publicy listed? | Yes, Biomaxima is a public company listed on WAR. |
| What is the stock symbol of Biomaxima? | Biomaxima trades under BMX ticker. |
| When did Biomaxima go public? | Biomaxima went public in 2010. |
| Who are competitors of Biomaxima? | Similar companies to Biomaxima include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Biomaxima? | Biomaxima's current market cap is $16.1M |
| What is the current revenue of Biomaxima? | Biomaxima's last 12 months revenue is $16.3M. |
| What is the current revenue growth of Biomaxima? | Biomaxima revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of Biomaxima? | Current revenue multiple of Biomaxima is 1.2x. |
| Is Biomaxima profitable? | Yes, Biomaxima is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biomaxima? | Biomaxima's last 12 months EBITDA is $2.0M. |
| What is Biomaxima's EBITDA margin? | Biomaxima's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Biomaxima? | Current EBITDA multiple of Biomaxima is 10.1x. |
| What is the current FCF of Biomaxima? | Biomaxima's last 12 months FCF is -$0.2M. |
| What is Biomaxima's FCF margin? | Biomaxima's last 12 months FCF margin is -1%. |
| What is the current EV/FCF multiple of Biomaxima? | Current FCF multiple of Biomaxima is -96.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
